Multidisciplinary Management of Metastatic Pancreatic Neuroendocrine Tumor Using a Combination of Beta, Alpha Radionuclide and Ethanol Ablation Therapies.

Clin Nucl MedApr 21, 2026 (epub)
Case ReportOncology (Medical)Gastroenterology

Piyush Aggarwal, Sahaj Rathi, Ashwani Sood et al.

✦ AI-curated · Sources linked

Case in brief

A young patient with metastatic pancreatic neuroendocrine tumor underwent peptide receptor radionuclide therapy (PRRT) using beta and alpha radionuclides. Following this treatment, endoscopic ultrasound (EUS)-guided ethanol ablation was performed on residual metastatic lymph nodes, resulting in a complete response. This case highlights the potential of combining systemic and local therapies for improved outcomes.

Diagnostic / clinical pearl

Combining endoscopic ultrasound-guided ethanol ablation with radionuclide therapy may enhance treatment efficacy in metastatic neuroendocrine tumors.

Why it matters

This case underscores the importance of considering local therapies in conjunction with systemic treatments, particularly in younger patients with longer life expectancies.

Source

PubMed · PMID 42080614

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.